Pharming (PHAR) Accounts Payables (2019 - 2026)

Pharming's Accounts Payables history runs 8 years deep, the most recent figure standing at $103.5 million for Q1 2026.

• Quarterly Accounts Payables rose 50.59% year-over-year to $103.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.5 million (up 50.59% YoY) and the FY2025 annual result came in at $105.9 million, up 58.98% from the prior year.
• Accounts Payables was $103.5 million for Q1 2026 at Pharming, down from $105.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $105.9 million in Q4 2025 and bottomed at $42744.0 in Q3 2022.
• A 5-year average of $64.9 million and a median of $68.5 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 99.9% — and 2023, when it surged 146212.93%.
• Pharming's Accounts Payables stood at $54.5 million in 2022, then soared by 33.16% to $72.5 million in 2023, then declined by 8.16% to $66.6 million in 2024, then surged by 58.98% to $105.9 million in 2025, then retreated by 2.24% to $103.5 million in 2026.
• Business Quant data shows PHAR's Accounts Payables at $103.5 million in Q1 2026, $105.9 million in Q4 2025, and $78.2 million in Q3 2025.